Immune Targeting Systems turns sights on commercial goals
This article was originally published in Scrip
By hiring two industry veterans, Immune Targeting Systems has flagged its intention to shift its focus to include commercial goals. The UK biotech focusing on the development of vaccines that promote T-cell responses to viruses and cancers has announced the appointment of Dr Benjamin Chen as executive chairman and Dr Kevin Fitzgerald as chief operating officer. Armed with Phase I data from two trials of the company's lead pandemic flu programme, the new leadership team intends to step up biopartnering activities and find a new investor to lead its existing backers in a series B round.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.